Hologic (HOLX)
(Delayed Data from NSDQ)
$80.76 USD
+0.38 (0.47%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $80.75 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.76 USD
+0.38 (0.47%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $80.75 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
BioScrip, Inc. (BIOS) reported net loss from continuing operations of $19.4 million or a loss of 18 cents per share in the first quarter of 2017 compared with net loss of $9.5 million or a loss of 17 cents a year ago.
Allscripts (MDRX) Beats on Q1 Earnings, Revenues In Line
by Zacks Equity Research
Allscripts Healthcare Solutions, Inc. (MDRX) reported first-quarter 2017 earnings of 10 cents per share, beating the Zacks Consensus Estimate by a penny.
Omnicell (OMCL) Q1 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Omnicell, Inc. (OMCL) reported a loss per share of 29 cents in first-quarter 2017, reflecting a deterioration from the year-ago loss of a penny.
Wright Medical (WMGI) Posts Wider-than-Expected Loss in Q1
by Zacks Equity Research
Wright Medical Group N.V. (WMGI) reported adjusted loss of 9 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 8 cents.
PerkinElmer (PKI) Tops Q1 Earnings Estimates, FY17 View Up
by Zacks Equity Research
PerkinElmer Inc (PKI) reported first-quarter 2017 adjusted earnings of 55 cents per share, marginally beating the Zacks Consensus Estimate by a penny.
athenahealth (ATHN) Earnings, Revenues Miss Estimates in Q1
by Zacks Equity Research
athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017.
AmerisourceBergen (ABC) Beats on Q2 Earnings, Lags Revenues
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) posted adjusted earnings of $1.77 per share in the second quarter of fiscal 2017, beating the Zacks Consensus Estimate of $1.71 and increasing 5.4% on a year-over-year basis.
Cardiovascular Systems (CSII) Swings to Earnings in Q3
by Zacks Equity Research
Cardiovascular Systems, Inc. (CSII) reported adjusted earnings per share of 3 cents in third-quarter fiscal 2017, reflecting a massive improvement from the year-ago quarter's adjusted loss of 47 cents.
Bruker (BRKR) Q1 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Bruker Corporation (BRKR) reported adjusted earnings per share (EPS) of 19 cents in the first quarter of 2017, lower than the year-ago figure by 9.5%.
DaVita (DVA) Earnings Miss Estimates, Revenues Beat in Q1
by Zacks Equity Research
DaVita Inc. (DVA) reported first-quarter 2017 adjusted operating earnings of 79 cents per share that missed the Zacks Consensus Estimate of 82 cents.
QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View
by Zacks Equity Research
QIAGEN N.V. (QGEN) reported first-quarter 2017 adjusted earnings per share (considering restructuring expenses as one time item) of 22 cents, up 15.8% year over year.
DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss
by Zacks Equity Research
DexCom Inc. (DXCM) reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents.
Myriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View
by Zacks Equity Research
Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 27 cents in the third quarter of fiscal 2017, down 34% year over year.
Amedisys (AMED) Beats on Q1 Earnings, Revenues Meet Mark
by Zacks Equity Research
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 47 cents per share in the first quarter of 2017, up 42.4% year over year.
CVS Health (CVS) Q1 Earnings Beat Estimates, Decrease Y/Y
by Zacks Equity Research
CVS Health Corporation (CVS) reported first-quarter 2017 adjusted earnings per share (EPS) of $1.17, down 0.8% year over year.
Ecolab (ECL) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Ecolab Inc. (ECL) reported first-quarter 2017 adjusted earnings (excluding special gains, charges and tax items) of 80 cents per share, which missed the Zacks Consensus Estimate of 81 cents.
Becton, Dickinson (BDX) Q2 Earnings Beat, Increase Y/Y
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, reported second-quarter fiscal 2017 earnings of $2.30 per share, which beat the Zacks Consensus Estimate of $2.23 and increased 5.5% on a year-over-year basis.
Luminex (LMNX) Tops Q1 Earnings, Revenue Guidance Raised
by Zacks Equity Research
Luminex Corporation (LMNX) reported earnings of 27 cents per share in the first quarter of 2017, surpassing the Zacks Consensus Estimate of adjusted earnings of 8 cents per share by a massive 237.5%.
Cardinal Health (CAH) Q3 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Cardinal Health Inc. (CAH) reported third-quarter fiscal 2017 adjusted earnings of $1.53 per share, which beat the Zacks Consensus Estimate of $1.46 and increased 7% on a year-over-year basis.
Hill-Rom (HRC) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
Hill-Rom Holdings, Inc. (HRC) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 88 cents, up 23.9% from the year-ago quarter.
Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates
by Zacks Equity Research
Accuray Inc.(ARAY) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny.
Is a Surprise in Store for Hologic (HOLX) in Q2 Earnings?
by Zacks Equity Research
Hologic Inc. (HOLX) is slated to report second-quarter fiscal 2017 financial results on May 10, after the closing bell.
Align Technology (ALGN) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Align Technology Inc. (ALGN) reported adjusted earnings per share (EPS) of 85 cents in the first quarter of 2017, up 70% from 50 cents posted in the year-ago quarter.
athenahealth (ATHN) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017, which missed the Zacks Consensus Estimate by a penny.
Chemed's (CHE) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Chemed Corp.'s (CHE) first-quarter 2017 adjusted earnings per share (EPS) (considering stock-based compensation expense and related tax benefit as a regular one) were $1.92, as compared to the year-ago adjusted EPS figure of $1.52, up 26.3% year over year.